Sarcomas

Michelle Ghert, MD, FRCSC, discusses the PARITY and SAFETY trials and the future of research in orthopedic oncology.

Joshua M. Lawrenz, MD, discusses a study looking at hypofractionated radiotherapy in soft tissue sarcoma.

Albert J. Aboulafia, MD, discusses advances in tenosynovial giant cell tumor and the early research and challenges in soft tissue sarcoma treatment.

William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.

Ibrahim S. Alshaygy, MD, MSC, discusses surgical developments in dermatofibrosarcoma protuberans and tenosynovial giant cell tumor.

Vincent Y. Ng, MD, discusses immunotherapy in micrometastatic high-risk soft tissue sarcoma.

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Vincent Y. Ng, MD, discusses what implications the NEXIS study could have in soft tissue sarcoma treatment and the next steps going forward.

C. Parker Gibbs Jr., MD, discusses the use of cell cycle checkpoint regulators to indicate response to treatment in osteosarcoma.

Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.

William Eward, MD, DVM, discusses the use of pexidartinib and other options to treat patients with tenosynovial giant cell tumor, as well as future recommendations for the field, such as using comparative oncology when researching drugs.

R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.

The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma to include a category 1 recommendation for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.

The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

The FDA has approved pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor that is associated with severe morbidity or functional limitations and not responsive to improvement with surgery.

The FDA has granted a priority review to tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Each year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

A new drug application has been submitted to the FDA for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor.

The FDA has granted a breakthrough therapy designation to pomalidomide for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the conditional marketing authorization for olaratumab be revoked following results of the ANNOUNCE study, which did not demonstrate a survival benefit with the PDGFRα antagonist in combination with doxorubicin versus doxorubicin alone in patients with advanced or metastatic soft tissue sarcoma.

Eli Lilly and Company has announced that it is withdrawing its PDGFRα antagonist olaratumab from the market for the treatment of patients with advanced soft tissue sarcoma.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 14, 2019, to discuss a new drug application for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.

A third of patients with advanced TRK fusion tumors had objective responses to the second-generation TRK inhibitor LOXO-195 after failure of initial anti-TRK therapy.